亚洲日韩欧美综合-亚洲日韩欧美一区二区在线-亚洲日韩欧美视频-亚洲日韩精品欧美一区二区-国产欧美日韩综合

會員登錄|免費注冊|忘記密碼|管理入口 返回主站||保存桌面|手機瀏覽|聯系方式|購物車
企業會員第1年

湖北大華偉業醫藥化工有限公司  

該公司主要從事原料藥(API)及中間體生產和研發

搜索
新聞中心
  • 暫無新聞
產品分類
  • 暫無分類
聯系方式
  • 聯系人:艾天堯
  • 電話:027-59420981
  • 郵件:1933329534@qq.com
  • 傳真:430000
  • QQ:1933329534
站內搜索
 
榮譽資質
  • 暫未上傳
友情鏈接
  • 暫無鏈接
首頁 > 供應產品 > 2,4-二羥基吡啶
2,4-二羥基吡啶
單價 面議對比
詢價 暫無
發貨 湖北武漢市付款后3天內
過期 長期有效
更新 2014-02-09 09:04
 
詳細信息

2,4-二羥基吡啶
中文品名:2,4-二羥基吡啶
中文別名:2,4-二羥基吡啶;2,4-二羥基吡啶,2,4-吡啶二醇;4-羥基-2-吡啶酮 
CAS NO: 626-03-9 
英文名稱:2,4-Dihydroxypyridine 
分子式:C5H5NO2 
分子量:111.1 
干燥失重:≤1.0% 
含量:≥99.0%
主要用途: 醫藥中間體 
包裝:5公斤/包,25公斤/桶

2,4-二羥基吡啶
中文品名:2,4-二羥基吡啶
中文別名:2,4-二羥基吡啶;2,4-二羥基吡啶,2,4-吡啶二醇;4-羥基-2-吡啶酮 
CAS NO: 626-03-9 
英文名稱:2,4-Dihydroxypyridine 
分子式:C5H5NO2 
分子量:111.1 
干燥失重:≤1.0% 
含量:≥99.0%
主要用途: 醫藥中間體 
包裝:5公斤/包,25公斤/桶
©2025 湖北大華偉業醫藥化工有限公司 版權所有   技術支持:化工網   訪問量:9631  
 
主站蜘蛛池模板: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |